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Abstract
Understanding the mutations that confer radiation resistance is crucial to developing mechanisms to subvert this resistance.
Here we describe the creation of a radiation resistant cell line and characterization of a novel p53 mutation. Treatment with
20 Gy radiation was used to induce mutations in the H460 lung cancer cell line; radiation resistance was confirmed by
clonogenic assay. Limited sequencing was performed on the resistant cells created and compared to the parent cell line,
leading to the identification of a novel mutation (del) at the end of the DNA binding domain of p53. Levels of p53, phospho-
p53, p21, total caspase 3 and cleaved caspase 3 in radiation resistant cells and the radiation susceptible (parent) line were
compared, all of which were found to be similar. These patterns held true after analysis of p53 overexpression in H460 cells;
however, H1299 cells transfected with mutant p53 did not express p21, whereas those given WT p53 produced a significant
amount, as expected. A luciferase assay demonstrated the inability of mutant p53 to bind its consensus elements. An MTS
assay using H460 and H1299 cells transfected with WT or mutant p53 showed that the novel mutation did not improve cell
survival. In summary, functional characterization of a radiation-induced p53 mutation in the H460 lung cancer cell line does
not implicate it in the development of radiation resistance.
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Introduction
Lung cancer is the number one cause of cancer-related deaths in
the United States, and account for 2.4% of all deaths worldwide
[1]. In 2009, over 200,000 new cases of lung cancer were
diagnosed, the majority of which were non-small cell lung cancer
(NSCLC) [2]. 2/3 of these patients will be given radiotherapy (RT)
as part of their treatment regimen. The success of RT in lung
cancer is greatly affected by a variety of factors including location,
size, grade, extent of invasion, and individual tumor characteris-
tics. Unfortunately, some of the cellular damage that causes cancer
can also induce resistance to treatments, making it a very real
concern. Understanding the genetic origins of these mutations is
crucial to developing mechanisms to subvert this resistance.
With the advent of genomic sequencing techniques, identifying
mutations in tumor samples has become commonplace, but this
influx of information does not always clearly indicate which of the
anomalies identified, if any, is responsible for therapeutic
resistance. Thus, many labs have begun engineering cell lines
expressing single mutations and using these to examine chemo-
and radioresistance. These lines can be studied directly. Alterna-
tively, some groups use molecular modeling to predict which
mutations will have functional consequences.
One of the most studied genes involved in cell cycle control is
p53, which operates as a cell cycle monitor; it has been implicated
in the regulation of both the G1/S and G2/M checkpoints via p21
[3]. p53 can also induce the caspase cascade, resulting in the
cleavage of caspase 3 and apoptosis [4–7]. Mutations in p53 have
been implicated in the development of ,50% of cancers,
including breast, colon, skin, brain, stomach, cervical, liver
esophageal, bladder, and lung cancers [8–32]. Studying these
mutations has revealed that many are also involved in radiation-
and chemoresistance.
We hypothesize that radiation resistance results from genetic
changes in cancer genomes, and have established a radiation-
resistant NSCLC cell line to serve as a cell model for us to
understand the molecular mechanism. Ion torrent analyses on this
cell line, in comparison with its original clone, identified several
mutations. One of these is a novel deletion mutant in p53. We
then performed functional characterization of this mutation to
determine its role in resistance to radiotherapy, and determined
that it was not a mechanism of resistance when WT p53 is also
present.
Results
Discovery and characterization of a novel
radiation-induced p53 deletion
The H460 lung cancer cell line has intact p53; treatment with
20 Gy radiation produced a small number of radiation-resistant
(RR) surviving cells, which were collected for study. Radiation
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resistance was confirmed by clonogenic assay (Fig. 1A), showing a
significant difference (p,0.007) in survival between the radiation
resistant cells and the parent cell line at doses as small as 4 Gy.
Sequencing analysis revealed a novel deletion at the end of the
DNA binding domain of p53 (Fig. 1B). This 4 amino acid deletion
generates a stop codon, resulting in a truncated protein missing the
C-terminal ,100 amino acids. The presence of the p53 deletion
was confirmed by Sanger sequencing, and the corresponding p53
deletion mutant protein was identified and confirmed by Western
blot analysis (Fig. 2).
Characterization of a novel p53 deletion mutant
To determine the effect of our novel deletion on cell survival
and the expression of p53 and downstream effector molecules
responsible for cell cycle arrest and apoptosis, a second radiation of
6 Gy was applied to cells from the parental and RR cells.
Subsequent protein expression was analyzed by Western blot
(Fig. 2). The parent and derivative cell lines were found to have
comparable levels of p21, total caspase 3 and cleaved caspase 3.
Levels of p53 and phosphorylated p53 were also comparable. As
expected, the radiation resistant samples showed two bands,
corresponding to normal and mutant p53 and their phosphory-
lated counterparts.
Notably, the expression of both p21 and cleaved caspase 3 is
delayed in the RR cell line. In the parent cell line, cleaved caspase
3 is apparent within 24 h of irradiation; in the RR-H460 line,
cleavage is delayed until 48 h post-irradiation. mRNA analysis of
p21 expression indicates that, 6 h post-irradiation, transcription is
higher in the RR cell line, but by 24 h post-irradiation the levels
are similar in the RR and parent cell lines (Fig. 2B).
p21 does not undergo significant transcriptional
activation by the deletion mutant
When WT or mutant p53 was overexpressed in the parental
H460 cell line, comparable levels of phosphorylated p53, total
caspase 3 and cleaved caspase 3 were expressed (Fig. 3A); higher
amounts of the truncated protein were produced as compared to
the full length transcript. A very minor increase in p21 expression
was also noted. Transfection of H1299 cells, which are naturally
p53 deficient, with mutant overexpressing plasmid did not induce
p21 expression, whereas those given WT p53 produced a
significant amount (Fig. 3B). Total and cleaved caspase 3 levels
were comparable. RT-PCR analysis confirmed that similar levels
of p21 were present in H460 cells transfected with the WT or
mutated p53 and that H1299 cells transfected with WT p53
expressed much higher levels of p21 than those transfected with
the mutant (Fig. 3C).
Deletion mutant does not impact cell survival unless
expression in isolation
The effect of this novel deletion on cell proliferation was
analyzed using an MTS assay. 48 h or 72 h after transfection with
WT p53, the survival rate for H1299 cells was 50%, whereas
transfection with mutant p53 resulted in over 90% survival (Fig. 4).
In H460 cells, survival was over 90% regardless of p53 status,
showing definitively that the novel deletion did not improve cell
survival when expressed in conjunction with WT p53, and did not
act as a dominant negative in the presence of WT p53.
Overexpression of deletion mutant does not confer
radiation resistance
Transfection of p53-competent cells with mutant p53 does not
change the survival capabilities of H460 cells after low-dose
radiation (Fig. 5).
Mutant p53 does not bind consensus elements
The development of luciferase reporter vectors has made
analysis of the effects of mutation on the binding ability of various
transcription factors quick and quantifiable. Examination of H460
cells transfected with WT p53 showed nearly twice the luciferase
expression as the control, whereas cells transfected with the
mutant p53 had slightly lower expression than the control (Fig. 6).
When the same vectors were applied to naturally p53-deficient
H1299 cells, the sample treated with the mutant p53 showed a
Figure 1. Identification of a novel radiation-induced p53 mutation that confers resistance to subsequent radiotherapy. H460 cells
(p53-competent) were exposed to sequentially higher doses of radiation, then incubated at 37uC for 8–10 days. One surviving (radiation-resistant)
clone was selected and expanded to create a radiation-resistance H460 cell line (RR-H460). To confirm the effect of novel deletion on cell survival, a
second radiation of 6 Gy was applied to cells from the parental and RR lines. A. Radiation resistance was confirmed by clonogenic assay after
treatment with 0–6 Gy. A significant (p,0.007) difference in survival between the radiation resistant colony and the parent cell line was noted at
doses of 4 or 6 Gy. SF = 0.2. B. Sequencing analysis revealed a novel deletion mutation at the end of the DNA binding domain of p53. Figure modified
from the TP53 website (p53.free.fr).
doi:10.1371/journal.pone.0087492.g001
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small amount of luciferase activity, approximately 36 that of the
vector, whereas the WT p53 induced 256 as much. These
luciferase assays demonstrated the inability of mutant p53 to
effectively bind its consensus elements, as evidenced by the failure
to initiate downstream gene transcription.
Discussion
This paper details the development of a radiation-resistant
NSCLC cell line, the identification of a novel p53 deletion mutant,
and subsequent functional characterization of this mutant.
Ultimately, while this novel mutant does have interesting
subcellular effects, it does not confer any survival advantage to
cancer cells when the cells also express WT p53.
Loss of the ability to control cell proliferation is the defining
characteristic of cancer; the proteins involved in this process are
thus critical to regulating growth and maintaining appropriate
proliferative capabilities. In 1979, one of the key proteins involved
in this process was discovered: p53 [11–13,30,33]. In its role as a
Figure 2. Characterization of parent and RR cell line after treatment with 6 Gy radiation. A. Subsequent protein expression was analyzed
by Western blot. The parent and derivative cell lines were found to have comparable levels of total caspase 3. Expression of p53, phosphorylated p53,
p21, and caspase cleavage were all delayed in the radiation resistant cell line. The radiation resistant cell line clearly shows two forms of p53, mutant
and WT. B. mRNA analysis of p21 expression indicates that, in the hours immediately after irradiation, transcription is initially higher in the RR cell line,
but by 24 h post-irradiation the levels are similar in the RR and parent cell lines.
doi:10.1371/journal.pone.0087492.g002
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transcription factor, p53 has been shown to interact with over 100
other proteins, including Nfkb, which is involved in transcription;
BRCA1 and PARP 1, which are responsible for DNA repair; and
Mdm2, which directly suppresses p53 activity [34–45]. Wild-type
p53 has a multitude of functions, all of which are involved in
regulating the cell cycle and suppressing neoplastic growth, and
which can be activated by a variety of pathways triggered by
cellular stress, including DNA damage and hypoxia [15,46]. These
functions include initiating cell cycle arrest and DNA repair, which
can inhibit the growth of potentially tumorigenic cells by moving
them to a state of senescence and/or apoptosis [47–48]. As such,
the integrity of p53 can determine the function or dysfunction of
hundreds of downstream effectors [46]. Thus, when we discovered
a novel p53 mutation in a radiation-resistant cell line, we chose to
focus our analysis on how it would affect the survival of lung
cancer cells.
Approximately 50% of all cancers have some type of mutation
in p53. ,75% of these mutations are missense mutations that
affect DNA binding, thus disabling the transcriptional function of
p53 [15,22,32]. The rest disrupt protein folding, effectively
destabilizing it [22]. The International Agency for Research on
Cancer currently has over 25,000 reported p53 mutations in their
database [22]. While most of these mutations are disabling, some
may lead to new functions for p53 that actually enhance
tumorigenic growth via aberrant DNA or protein binding
[22,32]; this may also enhance a tumor’s invasive capabilities
[46]. There have also been reports of p53 mutations that result in
EGRF inhibitor resistance [3]. Predominant are single base pair
alterations [19]; in lung cancer, these are most commonly GRT
transversions [10,19]. The variety of mutations that have been
described indicates that different subtypes of cancer may have
different biochemical origins [14].
p53 inactivation is typically the result of small changes in
sequence that result in dominant negative mutant forms of the
protein (90%) [49]. Such mutations have the potential to affect a
developing cancer in 2 ways: increasing DNA repair processes and
thus stunting tumor growth, or, by functional loss, allow the cell to
become more permissive regarding DNA damage. There are over
100 potential sites of damage known to cause phenotypic
mutations. As the whole protein consists of only 393 amino acids,
this indicates that the majority of mutations will result in some type
of altered function. Statistically, most p53 mutations occur at
positions 158, 175, 248 and 273 [50–51]; the mutation reported
herein, a deletion of bases 298–292, has never before been
reported in the literature. This deletion, located at the end of the
DNA binding domain of p53, generates a stop codon, resulting in
a truncated protein missing the C-terminal ,100 amino acids,
which includes the tetramerization domain (TD) and the C
terminal regulatory domain. Comparatively, mutations in these
domains are rare compared to those in the DNA binding domain
[18–19,23,28]. p53 in its active form preferentially acts as a
tetramer; this domain is facilitates appropriate post-translational
modification, proper DNA binding, and even degradation. Chene
notes that even a single mutation in the TD can have effects as
severe as those in the DNA binding domain [52]. Effects on post-
translational modification usually result in the failure to phos-
phorylate [53–54], or the inability to ubiquinate appropriately
[44,55]. However, the TD is not absolutely required for DNA
binding [56–62], due to the cooperative binding of monomers
(though this results in up to a 100-fold decrease in affinity [56].
When TD mutations are found in cancer, they are usually (22%)
found at the Arg342 residue and result in truncated proteins [18].
Mutations in p53 have been discovered in nearly every type of
cancer [8–32]; surprisingly, only a small number of these
mutations are in the DNA binding domain (see Table 1). While
many of these mutations appear during the development of a
primary cancer, radiation-induced p53 mutations have also been
implicated in a variety of secondary malignancies [1,25,63–74].
The H460 large cell lung cancer cell line is a hypotriploid human
cell line (modal number= 57) with normal p53 expression.
Previous publications have indicated that p53 status in H460 cells
affects survival post-radiation; Jung et al concluded that increased
radiosensitivity was mediated by PTEN expression via p53, and
Lee et al found that p53-inducible protein 3 was downregulated in
radiation-resistant H460 cells and its overexpression had signifi-
cant effects on radiosensitivity [75–76]. Thus, when we generated
Figure 3. Overexpression of the novel mutant p53 does not
induce p21 expression in p53-deficient H1299 cells. A.
Overexpression of WT p53 or the deletion mutant in H460 cells
resulted in higher expression of the truncated protein than the full
length transcript; comparable levels of phosphorylated p53, p21, total
caspase 3 and cleaved caspase 3 were observed. B. Overexpression of
the same in H1299 cells resulted in similar protein expression patterns
with the exception of p21, which was expressed as a result of
transfection with WT p53 but not the deletion mutant. C. RT-PCR
analysis confirms that similar levels of p21 are present in H460 cells
transfected with the WT or mutated p53 and that H1299 cells
transfected with WT p53 express much higher levels of p21 than those
transfected with the mutant.
doi:10.1371/journal.pone.0087492.g003
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a radiation-resistant H460 cell line and discovered a novel p53
mutation, its role in this resistance was of great interest.
After exposure of H460 cells to 20 Gy of radiation (less than the
typical total therapeutic dose; [77], we collected the surviving cells
for analysis, and confirmed resistance to subsequent lower doses of
radiation (Figure 1A). Sequence analysis of the selected clone
revealed a unique p53 mutation resulting in a truncated protein.
This nonsense mutation results in the loss the C-terminal ,100
amino acids, a sequence encoding the oligomerization domain and
the nuclear localization signal within it (see Figure 1B).
Comparison of the parent and radiation resistant cell lines after
treatment with 6 Gy radiation confirmed the presence of two
forms of p53 in the resistant cells (Figure 2A). Total caspase 3
production is comparable in both lines, but cleavage is delayed in
the radiation resistant line; p21 expression is also slightly delayed.
Interestingly, the level of p21 mRNA is higher in the radiation
resistant line in the hours immediately after irradiation (Figure 2B),
but at 24 h the two lines have approximately equal expression. As
this is not reflected in the level of protein expression, there must be
differential regulatory factors between the two lines. This could be
expressed either as a difference in gene transcription or in the
stability of the RNA itself.
In order to eliminate the effects of innate p53 expression, we
constructed an adenovirus-based vector containing either WT p53
or the sequence of the novel mutated form. Transfection with
these viral constructs allows overexpression of WT or mutated
p53, after which we analyzed the production of downstream
proteins p21 and caspase 3 (Figure 3A and B). Transfection of p53-
competent cells with the WT adenovirus (Fig. 3A) does not show
an increase in expression of p53 itself. The innate ability of H460
cells to produce WT p53, and thus p21, implies that there is also a
functioning regulatory system in place to modulate the levels of
these proteins being produced. This result is probably due to the
innate feedback mechanisms present in these cells that are lacking
in H1299 (p53-deficient) cells.
Unlike in the H460 system, p21 expression in H1299 cells was
only faintly detectable after transfection with the p53 mutant, but
strongly expressed after WT p53 was introduced (Fig. 3A and B);
this pattern was confirmed via RT-PCR (Fig. 3C). However, the
downstream target, caspase 3, is still produced in similar amounts
to that induced by WT p53, indicating that another, p53-
independent, process contributes to the induction protein expres-
sion in this cell line. Interestingly, though the level of total caspase
3 is similar in both the p53 competent and deficient cell lines,
H1299 cells show much greater levels of cleaved caspase 3. This
can be attributed to a higher innate sensitivity to transfection
toxicity.
The ultimate test of a novel mutation implicated in the
development of cancer is to examine the effect on cell
proliferation. To address this, we assessed the effect of overex-
pression of the novel mutant on the survival of p53-competent or –
Figure 4. Deletion mutant fails to improve cell survival when expressed in conjunction with WT p53. 48 h or 72 h after transfection with
WT p53, the survival rate for H1299 cells was 60%, whereas transfection with mutant p53 resulted in over 90% survival. In H460 cells, survival was over
90% regardless of p53 mutation status, showing definitively that the novel mutation did not improve cell survival unless present as the only available
form of p53, and confirming its inability to act as a dominant negative mutation.
doi:10.1371/journal.pone.0087492.g004
Figure 5. Overexpression of novel p53 mutation does not
confer radiation resistance. p53 variant does not affect radiation
resistance in the presence of WT p53. Transfection with WT p53 results
in slightly decreased survival after irradiation with 4 Gy, but there is no
difference in survival after exposure to 6 Gy. DER: (SF = 0.2); WT: 1.05
(p = 0.074); DEL: 0.97 (p = 0.27).
doi:10.1371/journal.pone.0087492.g005
Novel p53 Mutation Not Dominant Negative
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e87492
deficient lung cancer cells. Transfection of naturally p53-deficient
H1299 cells with WT p53 decreases survival by 40%; this effect
was not seen in p53-competent cells (Fig. 4). H460 cells had over
90% survival regardless of the type of p53 transfected, indicating
that long term survival is not significantly affected by the novel
mutant in the presence of WT p53; this confirms that this novel
deletion indeed does not function as a dominant negative.
However, it also does not confer any survival advantage. When
these transfected cells were exposed to increasing doses of RT, no
appreciable difference was seen in H460 cell survival (Fig. 5). At
Figure 6. Novel mutation abrogates p53 binding. Cells were transfected with a plasmid containing either WT p53 or that containing the novel
mutation. A. After transfection into p53 competent H460 cells, a luciferase assay shows WT p53 is capable of binding its consensus elements, whereas
mutant p53 is not. B. When the same vectors were applied to naturally p53-deficient H1299 cells, this difference was much more pronounced. The
sample transfected with the mutant p53 showed a small amount of luciferase activity, approximately 36 that of the vector, whereas the WT p53
induced 256 as much.
doi:10.1371/journal.pone.0087492.g006
Table 1. p53 mutations in cancer.
Number of p53 mutations with
reported effects
Number of nonsense mutations
(% of total)
Number of mutations in DNA binding domain
(% of total)
All cancers 28581 2326 (8.14) 567 (2.06)
Lung cancers 3075 277 (9.01) 58 (1.94)
Lung AC 819 60 (7.33) 19 (2.42)
Lung SCC 942 100 (10.62) 16 (1.76)
M lung AC 22 0(0) 2 (100)
M lung SCC 1 0 0
AC: adenocarcinoma.
SCC: squamous cell carcinoma.
doi:10.1371/journal.pone.0087492.t001
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lower radiation doses, WT p53 conferred a slightly significant
survival advantage in H1299 cells; however, after a dose of 6 Gy,
there was no difference in the survival of H1299 cells, regardless of
p53 mutation status.
Given the location of the reported deletion, we expect that there
might be two potential effects: abrogation of oligomerization and
of DNA binding.
The oligomerization domain is required for maximal p53
function, as it is most physiologically active when condensed into
tetramers [78]. Assessment of oligomerization efficiency can be
estimated by quantifying downstream protein expression. Normal
p53 tetramers function in cell cycle regulation via the induction of
p21 and the caspase cascade. Given this understanding regarding
the requirements for normal function, it is not surprising that the
mutant cell line being studied here showed delayed p21 and
caspase 3 expression (Fig. 2A). By the time p21 production has
reached its peak in the radiation resistant cells, it is already waning
in cells from the parent line; similarly, cleaved caspase 3 is
detectable within 24 h in the parent line, but not before 48 h in
the radiation resistant cells. Presumably, this novel deletion is
eventually compensated for by the persistence of one normal copy
of the p53 gene, indicating that a loss of homozygosity delays the
expression of apoptotic proteins, but ultimately is insufficient to
confer RR. This is surprising in light of the fact that the majority of
reported p53 mutations exhibit a dominant negative phenotype
[8,79], which provides a mechanism for their ability to control cell
cycle events even in a heterozygous state. Figure 2A confirms the
presence of residual normal p53 in the radiation resistant (RR) cell
line and the eventual production of similar amounts of p21 and
cleaved caspase 3. At 24 h, there is evidence of more apoptosis (ie
cleaved caspase 3) in the parental cell line, but total caspase
expression is equivalent. Thus, survival difference (see Fig. 1A) is
not due to apoptosis. Interestingly, p21 mRNA is actually greater
in the RR cells soon after irradiation (Fig. 2B). The lag in
expression must be due to other factors, one of which may be
irradiation itself [12,80].
The ability of p53 to bind its consensus elements is critical to its
function; without this binding, there can be no signaling induction.
In order to assess the effect of our novel deletion on p53 binding,
we used a luciferase assay to quantify the ability of cells transfected
with either WT or mutant p53 to instigate protein expression. In
the pGL3 luciferase reporter system (Promega), the gene of interest
is inserted into a vector containing a luciferase gene downstream of
the binding elements, providing a simple way to quantify the
induction of transcription post-consensus element binding. In
order to eliminate the effects of innate p53 expression, as in the
H460 cell line, we overexpressed either WT or mutated p53 in
H1299 cells, non-small cell lung carcinoma cells with homozygous
p53 dysfunction (ATCC), via modified adenovirus. Transfection of
H460 and H1299 cells with a modified adenovirus containing
either WT or mutated p53indicated that, as expected, this novel
deletion decreases the ability of p53 to bind DNA. When (WT)
H460 cells’ p53 content was boosted by transfection with WT p53,
luciferase expression doubled (Fig. 6). Adding mutant p53 actually
resulted in slightly reduced luminescence as compared to the
vector control, which is consistent with previous observations that
most p53 mutations are dominant negative [81–85], but not with
our data indicating that WT p53 is eventually able to compensate
for this deletion. This difference can be resolved by previous
observations that, while mutations in the DNA binding domain
can exhibit the dominant negative effect [8,86–87], this is lost
when the oligomerization domain is mutated [88–89]. Presum-
ably, p53’s dominant negative status depends on its ability to
combine with WT p53 via this domain. p53-deficient H1299 cells
showed a small increase in luciferase activity after the addition of
mutant p53, significantly less than that induced by transfection
with WT p53 (Fig. 6). Taken together, this data indicate that
mutant p53 is not able to efficiently bind its consensus elements.
In summary, we have generated a radiation resistant cell line
with a unique mutation resulting in a truncated p53 protein with
an altered DNA binding domain and deleted oligomerization
domain. This deletion causes a loss of function in the resulting
protein, as evidenced by the inability to induce the downstream
target p21, but also prevents the mutant protein from binding with
residual normal p53, thus abrogating its ability to act as a
dominant negative. Functional characterization of this novel
radiation-induced p53 deletion in the p53-competent H460 lung
cancer cell line does not implicate it in the development of
radiation resistance in the presence of a WT p53, as it ultimately
does not affect cell survival in a heterozygous mutant. During
subsequent, more extensive sequencing, additional mutations were
identified in the cellular genome of the radiation resistant colony;
one of these other genomic alterations may be responsible for the
radiation resistance seen in these cells. As the loss of p53 activity
characterizes its role in the development of cancer, and its ability
to override normal p53 functions can have serious consequences,
the identification of mutants that do not act as dominant negatives
may have important effects on treatment regimens for cancer
patients.
Materials and Methods
Ethics statement
None of the experiments in this paper require the approval of an
ethics committee; no patient samples or animals were used.
Cell culture and reagents
The human NSCLC cell line NCI-H460 (H460) and NCI-1299
(H1299) were obtained from the American Type Culture
Collection (ATCC). The cells were cultured in an environment
of 5% CO2 at 37uC in RPMI 1640 (Invitrogen) supplemented with
10% fetal bovine serum.
Creation of a radiation-resistant cell line
Radiation resistant H460 cells (RR-H460 cells) were selected.
Briefly, after H460 cells were treated with 20 Gy using a PanTak
310-keV X-ray machine, cells were cultured for seven days; the
surviving cells were trypsinized and cultured in 0.8% methylcel-
lulose supplemented with 20 ng/mL EGF (BD Biosciences),
bFGF, and 4 mg/mL insulin (Sigma). EGF, bFGF (20 ng/mL),
and insulin (4 mg/mL) were added every second day for 14 days to
allow the cells to form spheres. Spheres were diluted with PBS to
make a single-cell suspension and then plated in 100 mm dishes
with RPMI 1640 supplemented with 10% FBS. A single plaque
was chosen for expansion and subsequent characterization.
Ion torrent sequencing
Limited sequencing was performed on the resistant cell line
created and compared to the parent cell line. A sample from the
expanded clone was run on an Ion 314 chip in an Ion Torrent
PGM System.
Clonogenic survival assay
Radiation resistance was confirmed by clonogenic assay. Cells
were irradiated with 0–6 Gy (dose rate of 1.8 Gy/min) using 137Cs
irradiator (J.L. Shepherd and Associates). After irradiation, cells
were incubated at 37uC for 8–10 days. Cells were fixed for 15 m
with 3:1 methanol/acetic acid and stained for 15 m with 0.5%
Novel p53 Mutation Not Dominant Negative
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crystal violet (Sigma) in methanol. After staining, colonies were
counted by the naked eye (cut-off of 50 viable cells). The surviving
fraction was calculated as (mean colony counts)/(cells inocula-
ted)6(plating efficiency), with plating efficiency defined as (mean
colony counts)/(cells inoculated for irradiated controls). The dose
enhancement ratio (DER) was calculated as the dose (Gy) of
radiation that yielded a surviving fraction of 0.2 for H460 cells
divided by that for RR-H460 cells.
Cell viability assay
An MTS assay was performed using tetrazolium based CellTiter
96H AQueous One Solution Cell Proliferation assay (Promega).
H460and H1299 cells were seeded in 96 well plates at 3,000cells/
well. Cells were transfected with various plasmids and MTS assay
was performed at the indicated times.
Western blot analysis
Cells were washed twice with ice-cold PBS and then lysed in M-
Per mammalian lysis buffer (Thermo Scientific). The protein
concentration of the lysates was determined with the Bradford
reagent (Bio Rad), and equal amounts of protein were subjected to
SDS-PAGE of a 10% or 15% gel. Separated proteins were
transferred to a nitrocellulose membrane, which was then exposed
to 5% nonfat dried milk in TBS containing 0.1% Tween 20 (0.1%
TBST) for 1 h at room temperature and incubated overnight at
4uC with antibodies against caspase-3, phosphor-p53 (Cell
Signaling Technology), total p53, p21 (Santa Cruz Biotechnology)
or actin (Sigma). The membranes were then washed with
0.1%TBST before incubation with horseradish peroxidase–
conjugated goat antibodies to rabbit or mouse (Santa Cruz
Biotechnology). Immune complexes were detected with chemilu-
minescence reagents (Perkin-Elmer Life Science).
RNA extraction and RT-PCR
Cells were plated in 6-well plates and allowed to reach 80%
confluency. 1 mL of Trizol (Invitrogen; Carlsbad, CA) was added
into each well, and then RNA was extracted following the
manufacturer’s guidelines. RNA was further purified by the
RNAeasy kit (Qiagen). 2 mg of total RNA was reverse transcribed
using hexamer primer and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) in a final volume of 20 ml. 2 ml of
the cDNA was used for the PCR reactions to amplify the p21 gene
with ABI 7500 fast Real-Time System (Invitrogen). The sequences
of primers used were described previously [90]. Actin was used as
a control.
Plasmids, site-directed mutagenesis, transfection and
dual-luciferase assay
p53 expression plasmid was kindly provided by Dr. Steven
McMahon at Thomas Jefferson University. p53 deletion plasmid
was made using QuikChange II Site-Directed Mutagenesis Kits
(Agilent Technologies, Inc. Santa Clara, CA) to delete nucleotides
from 866 to 876. The primer sequences for deletion are as follows:
Forward Primer: 59-GCACAGAGGAAGAGAATCGGGGA-
GCCTCAC-39
Reverse Primer: 59-GTGAGGCTCCCCGATTCTCTTCCT-
CTGTGC-39.
H460, RR-H460 and H1299 cells were transfected 24 hr after
seeded in 6-well plate. Plasmids (1.5 mg) in 100 ml of serum-free,
antibiotic-free, opt-MEM (Invitrogen) were mixed with 5 ml
Lipofectamine 2000 transfection reagent (Invitrogen) dissolved in
100 ml of the same medium and allowed to stand at room
temperature for 20 min. The resulting 200 ml transfection
solutions were added to each well containing 2 ml medium. Six
hours later, the cultures were replaced with 2 ml fresh medium
supplemented with 10% FBS and antibiotics. For western blot,
cells were collected after and additional 48 hr. PG13-luc (wt p53
binding sites) was purchased from Addgene (Cambridge MA), wt
p53 binding sites were removed by digesting with Apa I and Xho I
to make pg13-Luc as a non-promoter control. H460 and H1299
cells were plated at 26104/well in 24-well format. 200 ng total
DNA were transfected with 0.6 ml lipofectamine 2000 (Invitrogen)
and Renilla Tk (Promega, Madison, WI) was used as a transfection
efficiency control. Luciferase activity is detected by dual-luciferase
kit (Promega).
Statistical Analysis
Standard error for all measured biological parameters is
displayed in the appropriate figures. Student’s t-test was utilized
to determine the significance between groups. Statistical analysis
was performed with Microsoft Excel. Significance was defined at
the level of p,0.05.
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